Paper41007114
Tumor-Immune Interactions in Pediatric Oral Rhabdomyosarcoma: A Narrative Review on Immuno-Oncology and Emerging Therapies.
El Meligy OA and 3 others. Children (Basel), 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Tumor-Immune Interactions in Pediatric Oral Rhabdomyosarcoma: A Narrative Review on Immuno-Oncology and Emerging Therapies. Papers, record 41007114. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41007114
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Tumor-Immune Interactions in Pediatric Oral Rhabdomyosarcoma: A Narrative Review on Immuno-Oncology and Emerging Therapies.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References167
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33816783 | Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma. | Mol Ther Oncolytics | 2021 | https://conductscience.org/library/papers/33816783 | PubMed |
| 2 | 39780248 | Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy. | Mol Cancer | 2025 | https://conductscience.org/library/papers/39780248 | PubMed |
| 3 | 36009387 | T-Cell Infiltration and Immune Checkpoint Expression Increase in Oral Cavity Premalignant and Malignant Disorders. | Biomedicines | 2022 | https://conductscience.org/library/papers/36009387 | PubMed |
| 4 | 40234830 | Myogenic IGFBP5 levels in rhabdomyosarcoma are nourished by mesenchymal stromal cells and regulate growth arrest and apoptosis. | Cell Commun Signal | 2025 | https://conductscience.org/library/papers/40234830 | PubMed |
| 5 | 31704149 | The PD-L1/PD-1 axis expression on tumor-infiltrating immune cells and tumor cells in pediatric rhabdomyosarcoma. | Pathol Res Pract | 2019 | https://conductscience.org/library/papers/31704149 | PubMed |
| 6 | 37132013 | Preclinical models for development of immune-oncology therapies. | Immuno-oncol Insights | 2022 | https://conductscience.org/library/papers/37132013 | PubMed |
| 7 | 34107450 | Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis. | Eur J Cancer | 2021 | https://conductscience.org/library/papers/34107450 | PubMed |
| 8 | 37854913 | Alveolar type of rhabdomyosarcoma of maxilla-A case report. | J Oral Maxillofac Pathol | 2023 | https://conductscience.org/library/papers/37854913 | PubMed |
| 9 | 34373263 | The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. | Cancer Discov | 2021 | https://conductscience.org/library/papers/34373263 | PubMed |
| 10 | 30413827 | Cytokines in clinical cancer immunotherapy. | Br J Cancer | 2019 | https://conductscience.org/library/papers/30413827 | PubMed |
| 11 | 35565399 | Optimizing Rhabdomyosarcoma Treatment in Adolescents and Young Adults. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35565399 | PubMed |
| 12 | 34113750 | Immune-Based Approaches for the Treatment of Pediatric Malignancies. | Annu Rev Cancer Biol | 2020 | https://conductscience.org/library/papers/34113750 | PubMed |
| 13 | 30364635 | Oncolytic Virus-Mediated RAS Targeting in Rhabdomyosarcoma. | Mol Ther Oncolytics | 2018 | https://conductscience.org/library/papers/30364635 | PubMed |
| 14 | 29029499 | Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children. | Oncotarget | 2017 | https://conductscience.org/library/papers/29029499 | PubMed |
| 15 | 31794912 | Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications. | Cancer Treat Rev | 2020 | https://conductscience.org/library/papers/31794912 | PubMed |
| 16 | 39963129 | CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma. | Front Immunol | 2025 | https://conductscience.org/library/papers/39963129 | PubMed |
| 17 | 37364231 | Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM. | JCO Precis Oncol | 2023 | https://conductscience.org/library/papers/37364231 | PubMed |
| 18 | 29891791 | TGF-β in T Cell Biology: Implications for Cancer Immunotherapy. | Cancers (Basel) | 2018 | https://conductscience.org/library/papers/29891791 | PubMed |
| 19 | 33182650 | Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33182650 | PubMed |
| 20 | 26173023 | IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas. | PLoS One | 2015 | https://conductscience.org/library/papers/26173023 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42646677 | Bidirectional Interplay Between Tumor Vaccines and the Tumor Microenvironment: Mechanisms, Cold-to-Hot Conversion, and Combination Strategies. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42646677 | PubMed |
| 41984108 | Immunotherapy for pediatric solid tumors: overcoming biological barriers through rational multimodal combinations. | Cancer Immunol Immunother | 2026 | https://conductscience.org/library/papers/41984108 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CD276 | 80381 | PubTator's text mining | https://conductscience.org/library/genes/80381 | NCBI Gene |
| FOXO1 | 2308 | PubTator's text mining | https://conductscience.org/library/genes/2308 | NCBI Gene |
| PAX3 | 5077 | PubTator's text mining | https://conductscience.org/library/genes/5077 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41007114
GET https://conductscience.org/api/papers/v1/41007114/references?page=2